Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ali R Jazirehi

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
International Journal of Molecular Sciences|November 13, 2021
Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell TherapyAli R Jazirehi
Anti-Cancer Drugs|August 4, 2010
Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapyAli R Jazirehi
Current Drug Delivery|March 14, 2012
Editorial: Functional complementation, molecular targeted strategies, and chemo/immuno-sensitization in cancer treatment: hurdles and solutionsAli R Jazirehi
Oncogene|March 25, 2005
Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic interventionAli R Jazirehi, Benjamin Bonavida
Epigenomics|December 23, 2014
Epigenomics and targeted therapy in cancerRamin Nazarian, Ali R Jazirehi
American Journal of Clinical and Experimental Immunology|July 26, 2013
Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistanceAli R Jazirehi, Dylan Arle
Molecular Cancer Therapeutics|January 30, 2004
Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosisAli R Jazirehi, Benjamin Bonavida
Methods in Molecular Biology (Clifton, N.J.)|April 26, 2011
Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapyAli R Jazirehi, Benjamin Bonavida
Epigenomics|December 6, 2013
TFPI2 methylation can serve as an epigenetic biomarker of metastatic melanomaRamin Nazarian, Ali R Jazirehi
Molecular Cancer Therapeutics|April 26, 2012
Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLsAli R Jazirehi, James S Economou
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
International Journal of Molecular Sciences|November 13, 2021
Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell TherapyAli R Jazirehi
Anti-Cancer Drugs|August 4, 2010
Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapyAli R Jazirehi
Current Drug Delivery|March 14, 2012
Editorial: Functional complementation, molecular targeted strategies, and chemo/immuno-sensitization in cancer treatment: hurdles and solutionsAli R Jazirehi
Oncogene|March 25, 2005
Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic interventionAli R Jazirehi, Benjamin Bonavida
Epigenomics|December 23, 2014
Epigenomics and targeted therapy in cancerRamin Nazarian, Ali R Jazirehi
American Journal of Clinical and Experimental Immunology|July 26, 2013
Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistanceAli R Jazirehi, Dylan Arle
Molecular Cancer Therapeutics|January 30, 2004
Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosisAli R Jazirehi, Benjamin Bonavida
Methods in Molecular Biology (Clifton, N.J.)|April 26, 2011
Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapyAli R Jazirehi, Benjamin Bonavida
Epigenomics|December 6, 2013
TFPI2 methylation can serve as an epigenetic biomarker of metastatic melanomaRamin Nazarian, Ali R Jazirehi
Molecular Cancer Therapeutics|April 26, 2012
Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLsAli R Jazirehi, James S Economou
Pageof 5